Subsidized direct-acting antiviral (DAA) treatment recently became available to all adults living with chronic hepatitis C virus (HCV) in Australia. Based on rapid uptake We assumed treatment and testing rates were initially higher for advanced fibrosis and the same across HCV transmission risk level sub-populations. We also assumed 
| INTRODUC TI ON
Globally, 71 million people are living with hepatitis C virus (HCV) infection. 1 In many countries, morbidity and mortality associated with HCV continue to rise. 2 The development of effective well-tolerated, once-daily and short duration direct-acting antiviral (DAA) therapy for the treatment of HCV infection has been revolutionary and provides an opportunity to stem rising liver disease burden. The WHO has set an ambitious goal to eliminate HCV as a major global public health threat by 2030. 3 Between 2015 and 2030, the WHO targets include increasing HCV diagnoses from 20% to 90% and the number of eligible persons receiving HCV treatment from <5% to 80%, reducing new infections by 80%, and HCV liver-related mortality by 65%. It will be critical for countries to evaluate progress against these WHO elimination targets.
In March 2016, Australia was one of the first countries to introduce Government-funded broad access to DAA therapy, with no restrictions based on liver disease stage, and drug and/or alcohol use. 4 Further, all physicians, including drug and alcohol specialists and general practitioners, were able to prescribe DAA therapies.
This unrestricted DAA access programme, an already high diagnosed proportion, 5 
| MATERIAL S AND ME THODS
We used the Bright model developed by the Center for Disease Analysis (CDA), which has been used by many countries to assess HCV epidemics and the impact of interventions. We updated a previous model 1, 8 for Australia to include data at the end of 2016 for HCV prevalence and number of diagnoses. The DAA uptake data are included at the end of 2017.
| Model structure
The Australian model has been described previously. Table 2 Total viraemic cases (2015) 227 310 [12] Newly HCV diagnoses (2015) 11 890 [12] Number of people treated Appendix, Table 1 [ 7, 31] Disease progression rates Acute to F0 4.4%-21.8% [32, 33] F0 to F1 3.4%-14.3% [32, 33] F1 to F2 4.5%-22.4% [32, 33] F2 to F3 4.7%-20.0% [32, 33] F3 to F4 0.24% [34] F3 to HCC 3.0% [34] F4 to DC 3.6% [26, 34] F4 to HCC 20.0% [24, 33, 35, 36] DC liver-related deaths 70.7% [33, 35, 36] HCC liver-related deaths 16.2% [33, 35, 36] 1st year 4.4%-21.8% [32, 33] Subsequent years 3.4%-14.3% [32, 33] Reduction in progression rate from F3 to HCC (cured) 77% [24] Reduction in progression rate from F4 to DC (cured) 76% [25, 26] Reduction in progression rate from F4 to HCC (cured) 77% [24] Reduction in liver-related mortality among cured DC and HCC population 50% Assumption (Sensitivity analysis from 0% to 80%,
Spontaneously clearance rate 20% [14] Background death rate 1.76% [37] SVR rate (F0-F3) 95% [38] [39] [40] [41] SVR rate (F4) 90% To test the impact of this assumption on our results, we performed a univariate sensitivity analysis varying this mortality reduction from 0% to 80% (Appendix S1). We assumed testing rates and current harm reduction programs remained in place from 2016, and only the impact of treatment uptake was analysed in this study.
Prior to the introduction of DAA therapy (initially through compassionate access in 2015), the model only considered interferon-based therapy with SVR rates depending on regimen and genotype. 10, 11 A distribution of 50% genotype 1 and 50% genotypes 2/3 among people receiving HCV treatment was assumed for interferon-based therapies. From 2016, we assumed that the SVR rates were solely based on the DAA treatment from clinical studies and reflected the disease stage at initiation (Table 1) .
| Data and point estimates of HCV epidemiology in Australia
The model requires an estimate for the number of people living with chronic HCV and incidence. We produced estimates for Australia in 2015 using HCV notifications (HCV antibody) data from 1991 to 2015. The chronic HCV prevalence for 2015 was then obtained by summing all notifications since 1991 and adjusting for spontaneous clearance, mortality, emigration, and cure through interferon and DAA treatment. 5, 12 Annual mortality rates were obtained from a linkage study conducted among people with HCV in New South Wales, Australia (1993-2012). 13 We assumed 20% of HCV-notified individuals (HCV antibody positive) had undergone spontaneous clearance. 14 The coverage of HCV treatment is the key input in the model.
We estimated the number of people receiving DAA treatment (estimated monthly) in 2016 and 2017 using the 10% random sample of Pharmaceutical Benefits Scheme patient level script claims data provided by the company Prospection.
6,7
| Model calibration
The model was calibrated to the prevalence of 227 310 and 11 890 new diagnoses in the year 2015 (Table 1) , 12 including the number of people receiving DAA from March 2016 to the end of the year.
6,7
Based on these data, the annual HCV incidence was calculated using a constant multiplier describing the relative incidence compared to the incidence in 1950 (Appendix S1). The annual incidence was then distributed to each age and gender cohorts using the HCV notifications data, followed by the age and gender distributions reported by Australian Bureau of Statistics (Australian Government) (Appendix S1). 17 We assumed this age and gender remained fixed at the 2016 distributions after 2017. Detailed methodology is explained in the Appendix S1. 
| Treatment roll-out scenarios

| RE SULTS
| Results for IFN-based scenario
The DC, decompensated cirrhosis; HCC, hepatocellular carcinoma.
TA B L E 2 (Continued)
| Impact of DAA treatment
In all DAA treatment scenarios, Australia had substantial reductions in chronic HCV prevalence (Figure 1 ), incidence and liver-related deaths ( Figure 2 ). In the pessimistic scenario, chronic HCV prevalence declined to 87 210 by 2030, 58% lower than the IFN-based scenario ( Figure 1 and Table 2 Table 2 ).
The model predicted rapid decreases in the size of the population who had HCV-related advanced liver disease (F4 including cirrhosis, DC, HCC and number who have received a liver transplant) ( Figure 3 and Table 2 ). For the pessimistic scenario, the model estimated cumulative number of 259 420 people (a 55% reduction)
would no longer reach advanced liver disease by 2030 compared to the IFN-based scenario. Corresponding estimates for the intermediate and optimistic scenarios were 346 970 (73% reduction) and 408 370 (86% reduction) cases averted, respectively ( Figure 3 and Figure 2 and Table 2 scenarios, respectively (Appendix S1).
The incidence of DC and HCC among the viraemic population decreased rapidly with the initial impact of DAA therapy in all scenarios (Table 2 and Appendix S1). The pessimistic scenario averted 580 new DC cases compared to the IFN-based scenario (59% lower, Table 2 and Appendix S1). The new DC cases were 93% lower than the IFN-based scenario in the intermediate scenario and the optimistic scenarios reduced DC incidence to 0 (Table 2 and Appendix S1). During 2016-2030, the cumulative 8020 HCC incidence cases were averted compared to the IFN-based scenario under the pessimistic scenario (56% reduction), with a 75%-88% reduction for the intermediate and optimistic scenarios compared to the IFN-based scenario ( Table 2 ).
| D ISCUSS I ON
Using an updated mathematical model incorporating DAA treatment, we determined that Australia can meet the 80% reduction of the broader population). 29 Fourth, we found our results were sensitive to the relative reduction in liver-related mortality among the cured DC and HCC population. Results from a linkage study being conducted in Australia will help us inform this parameter and improve our estimates. Fifth, there is evidence that disease progression transition rates change with age and sex, 30 but a single transition rate was used. Finally, the model incorporates an HCV reinfection incidence, but it does not include sub-population level risk such as PWID and HIV-infected MSM. Given that DAA uptake would appear to be even higher in Australia among these two high-risk populations, the model outcomes are likely conservative in relation to the potential HCV treatment as prevention benefit.
In conclusion, our analysis demonstrated that chronic HCV prevalence in Australia will decline substantially, and Australia could meet key WHO elimination targets around 2028. Achieving these targets in HCV prevalence and incidence will require continued effort and funding for harm reduction strategies, and sustained HCV testing and linkage to care to ensure people living with chronic HCV are diagnosed and treated. Unrestricted DAA access, including nonspecialist in prescribing, has established a solid foundation for HCV elimination, and these model-based outcomes provide crucial data to inform and help sustain these efforts. Squibb, has received research grant funding from Gilead, Merck,
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